Pulmonary Embolism After Sequential Use of Recombinant Factor VIIa and Activated Prothrombin Complex Concentrate in a Factor VIII Inhibitor Patient

Rosenfeld, Stephan B.; Watkinson, Karla K.; Thompson, Brad; Macfarlane, Donald E.; Lentz, Steven R.

doi:10.1055/s-0037-1613110

Cited by 57 publications

(47 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 patients with hemophilia A, and 15 patients with hemophilia B were reported to have had a venous thrombotic phenomenon [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases

Girolami

Scandellari

Zanon

et al. 2006

J Thromb Thrombolysis

View full text Add to dashboard Cite

All reported cases of non-catheter induced venous thrombosis in patients with hemophilia A or B have been carefully evaluated. A total of 27 cases were reported,12 patients with hemophilia A and 15 patients with hemophilia B. The age of patients varied between 9 and 67 years. There were 10 cases of deep vein thrombosis, 8 patients with pulmonary embolism accompanied or not by deep vein thrombosis, 5 cases of superficial vein thrombosis. In addition, there were 3 cases of thrombosis in unusual sites (1 retinal central vein thrombosis and 2 portal vein thrombosis). Finally, in one case, venous thrombosis was multiple. There was a fatality in a hemophilia B patient with pulmonary embolism. The most frequent risk or triggering factor in hemophilia A was the administration of Feiba or rFVIIa concentrates in patients with inhibitors. Surgery together with Prothrombin Complex concentrates was the most frequent cause in hemophilia B patients. Congenital associated prothrombotic risk factors were present in two patients. No or very few therapeutic procedures were initiated in these patients but for a suspension or reduction of concentrates infusion. In a few instances low molecular weight heparin was given for a few days. The frequent association of venous thrombosis with infusion of concentrates indicates the need for a careful evaluation of patients about to receive such therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases

Girolami

Scandellari

Zanon

et al. 2006

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

“…11 Rosenfeld et al described pulmonary embolism as a complication in a patient with hemophilia A and factor VIIa inhibitors. 12 In one of three patients with Glanzmann thrombasthenia treated with rFVIIa, severe thromboembolic Table 1 Prerequisites for the usage of factor VIIa in post-partum hemorrhage (adapted from Bomken et al 3 with permission)…”

Section: Discussionmentioning

confidence: 99%

Recombinant activated factor VII in the management of acute fatty liver of pregnancy: A case report

Supriya

Thunga

Narayanan

et al. 2015

J of Obstet and Gynaecol

View full text Add to dashboard Cite

A 20-year-old woman, primigravida at 36(+4) weeks' gestation presented with malaise, vomiting for 1 week, yellowish discoloration of the eyes for 3 days and loss of fetal movements. A clinical diagnosis of acute fatty liver with intrauterine fetal demise was made. Labor was induced with prostaglandin E2 gel and delivered vaginally. The post-partum period was complicated by atonic post-partum hemorrhage, an episode of seizure, recurrent hypoglycemic attack, hypokalemia and continuing coagulopathy. Supportive management in the intensive care unit using blood and blood products and injection recombinant activated factor VIIa to arrest the bleeding resulted in a successful outcome.

show abstract

“…3 This case is similar to an earlier report of a PE in a patient with SHA, which followed 12 days of therapy with both rFVIIa and FEIBA. 4 These two cases highlight the potential for thrombosis with the sequential use of bypassing agents. Clinicians and patients need to be aware of the benefits and risks associated with the use of rFVIIa and FEIBA, especially where novel therapeutic approaches are used.…”

Section: Dear Editor Antenatal Counselling: Documentation and Recallmentioning

confidence: 99%

“…However, information recall is poor, 2 especially in highly stressful situations such as labour, where distracting factors such as pain and anxiety may lead to discordance between parental and clinician recall of the conversation. 3,4 Post-counselling documentation is therefore critical in providing a record to which future health-care professionals can refer; for instance acting as a starting point for later discussions or as a form of legal document if advance treatment preferences are being decided. Despite this there has been little research into what is documented by clinicians after such discussions.…”

Section: Dear Editor Antenatal Counselling: Documentation and Recallmentioning

confidence: 99%

Antenatal counselling: Documentation and recall

Winckworth

Raj

Draper

et al. 2013

J Paediatrics Child Health

View full text Add to dashboard Cite

Pulmonary Embolism After Sequential Use of Recombinant Factor VIIa and Activated Prothrombin Complex Concentrate in a Factor VIII Inhibitor Patient

Cited by 57 publications

References 0 publications

Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases

Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases

Recombinant activated factor VII in the management of acute fatty liver of pregnancy: A case report

Antenatal counselling: Documentation and recall

Contact Info

Product

Resources

About